WE DON’T JUST SEE THE FUTURE.
WE KNOW HOW TO GET THERE.
Allogene is working to overcome the limitations of autologous CAR T immunotherapy by developing AlloCAR T™ therapies. The goal of our allogeneic platform is simple: combine gene-editing technology with cutting-edge cell-therapy manufacturing to deliver the clinical benefits of cell therapy. We start with T cells from healthy donors to allow for the creation of off-the-shelf inventory for the potential to treat all eligible patients faster, more reliably, and at greater scale.